Skapova D, Racil Z, Dvorakova D, Minarikova D, Mayer J
Department of Internal Medicine -- Hematooncology, University Hospital, Brno, Czech Republic.
Neoplasma. 2005;52(2):137-42.
Both early cytomegalovirus (CMV) monitoring and prophylactic antiviral therapy can decrease clinical complications or can prevent them in patients after allogeneic hematopoietic stem cell transplantation (HSCT). Presented paper summarizes experiences with using regular monitoring of reactivation of CMV after allogeneic HSCT by qualitative polymerase chain reaction (PCR) method to prevent the development of symptomatic CMV disease. Samples of peripheral blood leukocytes (PBL) in 71 patients were monitored. Because of retransplantation in two patients, 73 transplantations, each followed by the monitoring, were performed. Patients were monitored weekly after the transplantation for CMV DNA-emia in PBL. An episode of CMV infection representing an indication for preemptive ganciclovir (GCV) or foscarnet (FOS) therapy was defined as two consecutive positive PCR results in 4-7 days. Median time of monitoring was 313 days. The CMV infection was found in 28/73 monitorings (38.4%) and always was followed by preemptive therapy. One recurrence of CMV infection was observed in 4/28 (14.3%) monitorings and two recurrences in 1/28 (3.6%) monitorings. Presented approach resulted in complete prevention of overt CMV disease and this study enable to show that qualitative PCR method for determination of incipient CMV infection followed by preemptive therapy is suitable for preventing patients after allogeneic transplantation from CMV disease.
早期巨细胞病毒(CMV)监测和预防性抗病毒治疗均可减少异基因造血干细胞移植(HSCT)患者的临床并发症或预防并发症的发生。本文总结了采用定性聚合酶链反应(PCR)方法定期监测异基因HSCT后CMV再激活情况以预防症状性CMV疾病发生的经验。对71例患者的外周血白细胞(PBL)样本进行了监测。由于2例患者进行了再次移植,共进行了73次移植并均进行了监测。移植后每周对患者的PBL进行CMV DNA血症监测。将连续4 - 7天两次PCR结果呈阳性定义为CMV感染发作,提示需进行抢先使用更昔洛韦(GCV)或膦甲酸钠(FOS)治疗。中位监测时间为313天。在73次监测中有28次(38.4%)发现CMV感染,且均随后进行了抢先治疗。在28次监测中的4次(14.3%)观察到CMV感染复发,在28次监测中的1次(3.6%)观察到两次复发。所提出的方法完全预防了明显的CMV疾病,本研究表明,采用定性PCR方法测定早期CMV感染并随后进行抢先治疗适用于预防异基因移植患者发生CMV疾病。